The indication of Viagra "pulmonary hypertension" will be approved in China
-
Last Update: 2020-02-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Wen Jie winter On February 3, CDE formula proposed a batch of priority review and approval lists, including Pfizer's "sildenafil citrate tablets", which were included on the basis of rare diseases, and had been included in the list of clinically urgent overseas new drugs According to insight database, the application for listing of new indications of the drug was undertaken by CDE on September 26, 2019 (acceptance No.: jxhs1900118) At present, the technical review has been completed, and it has become "in approval" status It is expected to be approved for listing soon Sildenafil, a PDE5 inhibitor, was first approved for male erectile dysfunction (ED) in 1998 and for the treatment of pulmonary hypertension by FDA in November 2009 Pulmonary hypertension (PH) is a kind of pulmonary vascular disease With the continuous increase of pulmonary vascular resistance, it can eventually lead to heart and respiratory failure At present, pulmonary hypertension can not be cured, patients need to take medication for life.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
